X0201 3 2004-01-29 0 0001115285 EYETECH PHARMACEUTICALS INC EYET 0001106607 JP MORGAN PARTNERS BHCA LP C/O J.P. MORGAN PARTNERS, LLC 1221 AVENUE OF THE AMERICAS 40TH FLOOR NEW YORK NY 10020 0 0 1 0 0001243235 JPMP MASTER FUND MANAGER L P JP MORGAN PARTNERS LLC 1221 AVENUE OF THE AMERICAS 40TH FLOOR NEW YORK NY 10020 0 0 1 0 0001243236 JPMP CAPITAL CORP C/O J.P. MORGAN PARTNERS, LLC 1221 AVENUE OF THE AMERICAS 40TH FLOOR NEW YORK NY 10020 0 0 1 0 0000019617 J P MORGAN CHASE & CO 270 PARK AVE 39TH FL NEW YORK NY 10017 0 0 1 0 Director Stock Option (right to buy) 1.44 2002-12-03 2012-12-03 Common Stock 60000 I see footnote Series C-1 Convertible Preferred Stock Common Stock 1838235 D Series C-2 Convertible Preferred Stock Common Stock 1736111 D Series C-1 Warrant (right to buy) 2001-07-24 Common Stock 367647 D Series C-2 Warrant (right to buy) 2002-08-22 Common Stock 347222 D These options were granted to Damion Wicker and Srinivas Akkaraju, directors of the Issuer. Mr. Wicker is Managing Director of JPMP Capital Corp., the general partner of JPMP Master Fund Manager, L.P. ("MF Manager"), the general partner of J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA"). Mr. Akkaraju is a Principal at J.P. Morgan Partners, LLC and a limited partner of MF Manager. Mr. Wicker and Mr. Akkaraju are obligated to transfer any shares issued under the stock option to JPM BHCA. The Series C-1 and Series C-2 Convertible Preferred Stock is immediately exercisable. It has no expiration date. These shares will automatically convert into Common Stock of the Issuer , upon the close of the Issuer's public offering. These shares are convertible on a one for one basis. Warrant to purchase Series C-1 Convertible Preferred Stock at an exercise price of $6.80 per share. The Warrant expires upon the earlier of the closing of the Issuer's initial public offering of Common Stock and, July 23, 2008. The shares of Series C-1 Convertible Preferred Stock underlying the Warrant are convertible on a one for one basis into shares of Common Stock. Warrant to purchase Series C-2 Convertible Preferred Stock at an exercise price of $7.20 per share. The Warrant expires upon the earlier of the closing of the Issuer's initial public offering of Common Stock, and July 23, 2008. The shares of Series C-2 Convertible Preferred Stock underlying the Warrant are convertible on a one for one basis into shares of Common Stock. Damion E. Wicker 2004-01-29